Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo Company, Limited (hereafter,...
Read MoreDaiichi Sankyo Company, Limited (hereafter,...
Read MoreThe Freestyle Libre 14 Day...
Read MoreSandoz, a Novartis division and...
Read MoreFDA Committee Votes in Favor...
Read MoreNIH-funded researchers delayed signs of...
Read MoreBiomaterials are materials of natural...
Read MoreChina based I-Mab Biopharma, a...
Read MoreMillions of people in WHO's...
Read MoreKeytruda, Merck’s anti-PD-1 therapy, has...
Read More